{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:01:53Z","timestamp":1773770513339,"version":"3.50.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Radioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control.<\/jats:p>\n            <jats:p>We analyzed all patients with IRTC and ATC who underwent commercially available NGS in 3 cancer centers.<\/jats:p>\n            <jats:p>Twenty-two patients were identified, 16 patients with IRTCs and 6 patients with ATCs. Eighteen (82%) had targetable findings in NGS, nine patients were treated accordingly. Median progression-free survival for targeted treatment was 50 months [95% confidence interval (CI95%) 9.8\u201366.6] and2 months (CI95% 0.2\u201316.5) for IRTC and ATC, respectively. Of 4 patients who achieved durable responses of 7 to 50 months, 2 are ongoing. The estimated median OS of IRTC receiving targeted treatment was not reached (CI95% 89.7\u2013111.4 months) and was 77.8 months (CI95% 52.5\u2013114.6) for patients treated conventionally (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.3).<\/jats:p>\n            <jats:p>NGS may detect clinically significant genetic alterations and benefit patients with advanced thyroid cancers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026388","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:41:43Z","timestamp":1624455703000},"page":"e26388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?"],"prefix":"10.1097","volume":"100","author":[{"given":"Assaf","family":"Moore","sequence":"first","affiliation":[{"name":"Institute of Oncology, Davidoff Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Bar","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University"},{"name":"Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Maurice-Dror","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Rambam Health Care Campus"},{"name":"Ruth & Bruce Rappaport, Faculty of Medicine, Technion Israel Institute of Technology, Haifa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inbar","family":"Finkel","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Davidoff Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Goldvaser","sequence":"additional","affiliation":[{"name":"Oncology Institute, Shaare Zedek Medical Center"},{"name":"The Hebrew University Faculty of Medicine, Jerusalem, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Dudnik","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Davidoff Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Davidoff Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Gordon","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Davidoff Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem","family":"Billan","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Rambam Health Care Campus"},{"name":"Ruth & Bruce Rappaport, Faculty of Medicine, Technion Israel Institute of Technology, Haifa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orit","family":"Gutfeld","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University"},{"name":"Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Wolf","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University"},{"name":"Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Popovtzer","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Davidoff Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva"},{"name":"Sackler Faculty of Medicine, Tel Aviv University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.cco.0000198975.36368.d3","article-title":"Thyroid carcinoma","volume":"18","author":"Weber","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet (London, England)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1098-2388(199901\/02)16:1<34::AID-SSU7>3.0.CO;2-2","article-title":"Management of the patient with progressive radioiodine non-responsive disease","volume":"16","author":"Haugen","year":"1999","journal-title":"Semin Surg Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJM197401242900404","article-title":"Chemotherapy of thyroid cancer with adriamycin","volume":"290","author":"Gottlieb","year":"1974","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR( Rearrangement in Thyroid Tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-17-0871","article-title":"Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy","volume":"17","author":"Chen","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"45784","DOI":"10.18632\/oncotarget.17412","article-title":"Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/15384047.2018.1523856","article-title":"Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer","volume":"20","author":"Guo","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.13942","article-title":"Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing","volume":"75","author":"Duan","year":"2019","journal-title":"Histopathology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.29089","article-title":"Clinical next-generation sequencing in patients with non-small cell lung cancer","volume":"121","author":"Hagemann","year":"2015","journal-title":"Cancer"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hed.26026","article-title":"Next-generation sequencing in salivary gland carcinoma: targetable alterations lead to a therapeutic advantage-Multicenter experience","volume":"42","author":"Moore","year":"2020","journal-title":"Head Neck"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/15384047.2018.1480289","article-title":"Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations","volume":"19","author":"Ofir Dovrat","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet (London, England)"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"(Suppl 1)","key":"R30-20250504","first-page":"A4","article-title":"Activity of larotrectinib in patients with advanced TRK fusion thyroid cancer","volume":"28","author":"Brose","year":"2018","journal-title":"Thyroid"},{"key":"R31-20250504","first-page":"352","article-title":"Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update","volume":"12","author":"Mendoza","year":"2018","journal-title":"Oncol Rev"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-15-2568","article-title":"Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/thy.2011.0117","article-title":"Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma","volume":"22","author":"Xu","year":"2012","journal-title":"Thyroid"},{"key":"R40-20250504","first-page":"4259","article-title":"BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers","volume":"6","author":"Shih","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"(15_suppl)","key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2020.38.15_suppl.1002","article-title":"TBCRC 048: a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2011.02161.x","article-title":"Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer","volume":"103","author":"Park","year":"2012","journal-title":"Cancer Sci"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Invest New Drugs"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acsmedchemlett.5b00001","article-title":"Discovery of clinical candidate BMS-906024: a potent Pan-Notch inhibitor for the treatment of leukemia and solid tumors","volume":"6","author":"Gavai","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1535-7163.MCT-17-0001","article-title":"Notch inhibitor PF-03084014 inhibits hepatocellular carcinoma growth and metastasis via suppression of cancer stemness due to reduced activation of Notch1-Stat3","volume":"16","author":"Wu","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"a000539","DOI":"10.1101\/mcs.a000539","article-title":"Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the (-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case","volume":"1","author":"Knoechel","year":"2015","journal-title":"Cold Spring Harb Mol case Stud"},{"issue":"(15_suppl)","key":"R47-20250504","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1200\/JCO.2016.34.15_suppl.6091","article-title":"Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study","volume":"34","author":"Mehnert","year":"2016","journal-title":"J Clin Oncol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"viii646","DOI":"10.1093\/annonc\/mdy302.004","article-title":"Lenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)","volume":"29","author":"Dierks","year":"2018","journal-title":"Ann Oncol"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"OF8L","DOI":"10.1158\/2159-8290.CD-RW2019-017","article-title":"Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis","volume":"9","author":"Yin","year":"2019","journal-title":"Cancer Discov"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1556-0864(18)30419-2","article-title":"145P Impact of next-generation sequencing on survival in lung cancer","volume":"13","author":"Geva","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa Multiple Basket Study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:05:57Z","timestamp":1746338757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026388"}},"subtitle":["A multicenter experience"],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":49,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026388","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2021-01-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}